Where there is inflammation, treatment may reduce disability progression – Commentary-Reference-Cited by-同舟云学术

Where there is inflammation, treatment may reduce disability progression – Commentary

Published:2018-10-08 Issue:14 Volume:24 Page:1812-1814
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Rube Jacob¹,Lisak Robert P²

Affiliation:

1. Department of Neurology, School of Medicine, Wayne State University and Detroit Medical Center, Detroit, MI, USA

2. Department of Neurology, School of Medicine, Wayne State University and Detroit Medical Center, Detroit, MI, USA/Department of Biochemistry Microbiology and Immunology, School of Medicine, Wayne State University and Detroit Medical Center, Detroit, MI, USA

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1352458518799639

Reference15 articles.

1. Where there is inflammation, treatment may reduce disability progression – No

2. Where there is inflammation, treatment may reduce disability progression – Yes

3. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

4. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

5. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis;Multiple Sclerosis Journal;2020-01-21